Biocon Breaks New Ground: First Generic Liraglutide Approved in UK

Biocon Limited has achieved a significant milestone by becoming the first generics company to receive approval for Liraglutide in the UK. The Medicines and Healthcare Products Regulatory Agency (MHRA) granted approval for Biocon's complex formulation of Liraglutide (6mg/ml solution for injection in pre-filled pen) on March 27, 2024. This approval covers both diabetes treatment (gVicotza®) and weight management (gSaxenda®) indications. Biocon will partner with Zentiva to commercialize the product in the UK, tapping into a market opportunity worth $425 million. The company's shares rose over 3% on the NSE following the announcement, trading at ₹266 apiece as of February 28, 2025.

 

Sources: Biocon Press Release, NSE, BSE, Moneycontrol